The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
Official Title: An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib
Study ID: NCT00486538
Brief Summary: This study is designed to determine the clinical efficacy and toxicity of ABT 869 in the treatment of subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Site Reference ID/Investigator# 7193, Sacramento, California, United States
Site Reference ID/Investigator# 5243, Washington, District of Columbia, United States
Site Reference ID/Investigator# 5384, Chicago, Illinois, United States
Site Reference ID/Investigator# 11662, Boston, Massachusetts, United States
Site Reference ID/Investigator# 11663, Boston, Massachusetts, United States
Site Reference ID/Investigator# 5379, Boston, Massachusetts, United States
Site Reference ID/Investigator# 5380, Lebanon, New Hampshire, United States
Site Reference ID/Investigator# 5249, Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 6278, Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 6269, Pittsburgh, Pennsylvania, United States
Site Reference ID/Investigator# 7300, Charleston, South Carolina, United States
Site Reference ID/Investigator# 6796, Houston, Texas, United States
Site Reference ID/Investigator# 6566, Vancouver, , Canada
Name: Justin L. Ricker, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR